Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bionano Genomics's revenue for the
three
months ended in Jun. 2026 was MXN142.6 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was MXN541.5 Mil.
Bionano Genomics's Revenue per Share for the
three
months ended in Jun. 2026 was MXN12.35.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was MXN61.98.
Warning Sign:
Bionano Genomics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Bionano Genomics was -74.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -55.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -30.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 10 years, Bionano Genomics's highest 3-Year average Revenue per Share Growth Rate was 9.10% per year. The lowest was -70.50% per year. And the median was -47.80% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Bionano Genomics Revenue Related Terms
Bionano Genomics Revenue Historical Data
* Premium members only.
The historical data trend for Bionano Genomics's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Bionano Genomics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionano Genomics Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Revenue distribution charts can be found below:
* The bar in red indicates where Bionano Genomics's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN541.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionano Genomics (MEX:BNGO) has a Revenue of MXN541.5 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Bionano Genomics and its competitors.
Is Bionano Genomics' Revenue too high?
Bionano Genomics' current Revenue is MXN541.5 Mil. Overall, Bionano Genomics has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' Revenue compare to RGNT and UEEC?
Bionano Genomics' Revenue of MXN541.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Bionano Genomics and its competitors. Bionano Genomics's current Revenue is MXN541.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Based on GuruFocus' analysis, Bionano Genomics (MEX:BNGO) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN15.75, compared to a current price of MXN19.99 — trading 26.9% above its estimated fair value. The current Revenue is MXN541.5 Mil. Bionano Genomics' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Bionano Genomics (MEX:BNGO), the current Revenue is MXN541.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionano Genomics (MEX:BNGO) Overvalued in 2026?
Based on GuruFocus' analysis, Bionano Genomics stock appears to be overvalued.
The current stock price of MXN19.99 is trading 26.9% above its estimated GF Value™ of MXN15.75.
GuruFocus considers Bionano Genomics to be Modestly Overvalued.
Key valuation signals for MEX:BNGO:
Revenue: MXN541.5 Mil
GF Value™: MXN15.75 vs. price of MXN19.99 (26.9% above fair value)
No single metric tells the full story. See the MEX:BNGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
63GF Score
Get the complete analysis for MEX:BNGO
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BNGO has been successfully added to your 
